Drug Profile
RES 420
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator PharmaMax
- Class Antivirals
- Mechanism of Action Viral protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Viral-infections in China (Intranasal, Spray)
- 01 Aug 2016 PharmaMax has patent protection for RES 420 in China before August 2016
- 01 Aug 2016 Clinical trials in Viral infections in China (Intranasal) before August 2016